JP2006505622A - 抗菌活性を有する新規化合物 - Google Patents
抗菌活性を有する新規化合物 Download PDFInfo
- Publication number
- JP2006505622A JP2006505622A JP2005501280A JP2005501280A JP2006505622A JP 2006505622 A JP2006505622 A JP 2006505622A JP 2005501280 A JP2005501280 A JP 2005501280A JP 2005501280 A JP2005501280 A JP 2005501280A JP 2006505622 A JP2006505622 A JP 2006505622A
- Authority
- JP
- Japan
- Prior art keywords
- group
- mmol
- ethyl
- ylmethyl
- yield
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/18—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Abstract
Description
本発明は、一般式(I)の化合物、あるいはそれらの薬理学的に許容可能な塩、溶媒和物、水和物又は薬理学的に許容可能な配合物に関する:
Aは、酸素、硫黄もしくは窒素原子、又はC1〜4アルキレン、C2〜4アルケニレン、C2〜4アルキニレンもしくはC1〜4ヘテロアルキレン基であり、
X1、X2、X3、X4及びX5は、それぞれ他のものと独立して、窒素原子又は式CR2の基であり、
R1は、水素原子、ハロゲン原子、ヒドロキシ基、アルキルオキシ基又はヘテロアルキルオキシ基であり、
R2は、水素原子、ハロゲン原子、又はヒドロキシ、アルキル、アルケニル、アルキニルもしくはヘテロアルキル基であり、
R3は、次の基から選択され:
R5は、アルキル、アルケニル、アルキニル、ヘテロアルキル、アリール、ヘテロアリール、シクロアルキル、アルキルシクロアルキル、ヘテロアルキルシクロアルキル、ヘテロシクロアルキル、アラルキル又はヘテロアラルキル基であり、
nは、0、1、2又は3であり、
mは、0又は2である。
1.a) (3RS)−アジドメチルピペリジン−1−カルバミン酸ベンジル:
1H−NMR(CDCl3、300MHz:1.28(m、1H);1.51(m、1H);1.60−1.87(m、3H);2.74(br s、1H);2.91(m、1H);3.23(br d、J=4.5Hz、2H);3.98(td、J=4.1、13.2Hz、1H);4.06(br s、1H);5.15(s、2H);7.28−7.38(m、5H).
MS(EI) m/z 249[M+H]+
MS(EI) m/z 397[M+H]+
MS(EI) m/z 308[M+H]+
MS(EI) m/z 202[M+H]+
MS(EI) m/z 464[M+H]+
2.a) (3RS)−(t−ブトキシカルボニルアミノ−メチル)ピペリジン−1−カルバミン酸ベンジル
MS(EI) m/z 349[M+H]+
MS(EI) m/z 215[M+H]+
MS(EI) m/z 416[M+H]+
MS(EI) m/z 316[M+H]+
MS(EI)m/z 456[M+H]+
5a) (3S)−アミノメチル−ピペリジン−1−カルバミン酸t−ブチル
MS(EI) m/z 215[M+H]+
MS(EI) m/z 349[M+H]+
MS(EI) m/z 249[M+H]+
MS(EI) m/z 450[M+H]+
MS(EI) m/z 316[M+H]+
MS(EI)m/z 477[M+H]+
8.a) (3S)−{[(2,3−ジヒドロ−ベンゾ[1,4]ジオキシン−6−イルメチル)アミノ]メチル}ピペリジン−1−カルバミン酸t−ブチル
MS(EI)m/z 363.4[M+H]+
反応混合物を濃縮して、2N NaOH水溶液に溶解した。水相をジクロロメタン/MeOH(9/1)で抽出して、合わせた有機相を硫酸ナトリウムで乾燥し、濾過して、回転蒸発により濃縮乾固した。
MS(EI) m/z 263.4[M+H]+
10.a) 8−([2−(6−メトキシキナゾリン−4−イル)エチル]−1,4−ジオキサスピロ[4.5]デカン−8−オール
MS(EI) m/z 344[M+H]+
MS(EI) m/z 301[M+H]+
MS(EI) m/z 436[M+H]+
11.a) 4−アミノ−1−[2−(6−メトキシキナゾリン−4−イル)エチル]シクロヘキサノール
MS(EI) m/z 302[M+H]+
MS(EI) m/z 450[M+H]+
16a) 8−(6−メトキシ−[1,5]ナフチリジン−4−イルエチニル)−1,4−ジオキサスピロ[4.5]デカン−8−オール
MS(EI) m/z 341[M+H]+
MS(EI) m/z 334.4[M+H]+
MS(EI) m/z 301[M+H]+
17.a) 4−[2−(6−エトキシ−キノリン−4−イル)エチル]−4−ヒドロキシシクロヘキサノン
18.a) 4−アミノ−1−[2−(6−メトキシ−[1,5]ナフチリジン−4−イル)エチル]シクロヘキサノール
MS(EI) m/z 302[M+H]+
20.a) 4−アミノ−1−[2−(6−メトキシキノリン−4−イル)エチル]シクロヘキサノール
MS(EI) m/z 435[M+H]+
29.a) 8−エチニル−1,4−ジオキサスピロ[4.5]デカン:
H(CDCl3、300MHz):1.61(m、2H);1.70−1.94(m、6H);2.07(d、J=2.5Hz、1H);2.51(m、1H);3.96(s、4H).
MS(EI) m/z 324[M+H]+
MS(EI) m/z 328[M+H]+
MS(EI) m/z 284[M+H]+
MS(EI) m/z 419[M+H]+
30.a) 7−[(ベンジル−{4−[2−(6−メトキシキノリン−4−イル)エチル]シクロヘキシル}アミノ)メチル]−4H−ベンゾ[1,4]オキサジン−3−オン
MS(EI) m/z 536[M+H]+
MS(EI) m/z 446[M+H]+
31.a) (3RS)−[(2,3−ジヒドロベンゾ[1,4]ジオキシン−6−イルメチル)アミノ]ピロリジン−1−カルバミン酸ベンジル
H(CDCl3、300MHz):1.57(br s、1H)、1.77(m、1H)、2.07(m、1H);3.21(m、1H);3.37(m、2H);3.61(m、2H)、3.70(s、2H);4.25(s、4H);5.14(s、2H);6.76−6.84(m、3H);7.30−7.38(m、5H).
MS(EI) m/z 235[M+H]+
MS(EI) m/z 436.5[M+H]+
MS(EI) m/z 422[M+H]+
MS(EI) m/z 410[M+H]+
34.a) 4−オキソアゼパン1−カルバミン酸t−ブチル
1H−NMR(CDCl3、300MHz):1.46(s、9H);1.80(br、2H);2.60−2.7(m、4H);3.4−3.6(m、4H).
MS(EI) m/z 215.6[M+H]+
1H−NMR(CDCl3、300MHz):1.46(s、9H);1.5−1.75(m、2H);1.8−2.05(m、4H);2.65(m、1H);3.1−3.6(m、4H);3.70(s、2H);4.26(s、4H);6.8−6.9(m、3H).
MS(EI) m/z 363.6[M+H]+
MS(EI) m/z 263.4[M+H]+
MS(EI) m/z 464.6[M+H]+
35.a) (4RS)−[(6−メトキシキノリン−4−イルメチル)アミノ]アゼパン−1−カルバミン酸t−ブチル
1H−NMR(CDCl3、300MHz):1.47(s、9H);1.5−2.0(m、8H);2.8−2.9(m、1H);3.2−3.65(m、5H);3.97(s、3H);4.22(s、2H);5.25−5.35(m、1H);6.6−6.8(m、2H);7.11(dd、1H);7.35−7.45(m、3H);8.02(d、J=9.2Hz、1H);8.73(d、J=1.4Hz、1H).
MS(EI) m/z 386.5[M+H]+
1H−NMR(CDCl3、300MHz):1.7−2.3(m、6H);3.0−3.3(m、4H);3.35−3.45(m、1H);3.97(s、3H);4.2(s、2H);7.28(d、1H);7.35−7.45(m、2H);8.02(d、J=9.2Hz、1H);8.73(d、J=1.4Hz、1H).
MS(EI) m/z 286.3[M+H]+
1H−NMR(CDCl3、300MHz):1.40−2.05(m、6H);2.35−2.80(m、3H);2.8−2.9(m、1H);3.41(2、2H);3.99(s、3H);4.15(s、2H);4.20(s、4H);6.70−6.80(m、3H);7.37(dd、J=2.76、J=9.1、1H)7.45(d、J=2.76、1H);7.51(d、J=4.4、1H);7.92(d、J=9.12、1H);8.65(d、J=4.4、1H).
MS(EI) m/z 434.7[M+H]+
MS(EI) m/z 416.6[M+H]+
40.a) 1−[2−ヒドロキシ−2−(6−メトキシキノリン−4−イル)エチル]−[1,4]−ジアゼパン−5−カルボン酸t−ブチルエステル
MS(EI) m/z 402.5[M+H]+
MS(EI) m/z 506[M+H]+
MS(EI) m/z 450[M+H]+
40.d) 1−[2−ヒドロキシ−2−(6−メトキシキノリン−4−イル)エチル]−4−(3−フェニルプロピル)−[1,4]ジアゼパン−5−カルボン酸t−ブチルエステル、及び
40.e)1−[2−ヒドロキシ−2−(6−メトキシキノリン−4−イル)エチル]−4−(3−フェニルプロピル)−[1,4]ジアゼパン−5−カルボン酸。
40.f)4−ヘプチル−1−[2−ヒドロキシ−2−(6−メトキシキノリン−4−イル)エチル]−[1,4]ジアゼパン−5−カルボン酸t−ブチルエステル、及び
40.g)4−ヘプチル−1−[2−ヒドロキシ−2−(6−メトキシキノリン−4−イル)エチル]−[1,4]ジアゼパン−5−カルボン酸を調製した。
MS(EI) m/z 450[M+H]+
42.a) 4−(6−メトキシキナゾリン−4−イルオキシメチル)シクロヘキサノール
MS(EI) m/z 289[M+H]+
MS(EI) m/z 287.1[M+H]+
MS(EI) m/z 287.1[M+H]+
MS(EI) m/z 288[M+H]+
MS(EI) m/z 436[M+H]+
MS(EI) m/z 422[M+H]+
48.a) トランス−4−t−ブトキシカルボニルアミノシクロヘキサンカルボン酸
MS(EI) m/z 242.4[M+H]−)
(MS(EI) m/z 387[M+H]+)
(MS(EI) m/z 287[M+H]+)
50.a) 4−(6−メトキシ−[1,5]ナフチリジン−4−イルオキシメチル)シクロヘキシルアミン
52.a) {8−[(2RS)−ヒドロキシ−2−(6−メトキシキノリン−4−イル)エチル]−8−アザビシクロ[3.2.1]オクタ−3−イル}カルバミン酸t−ブチル
59.a) 5−アジドメチル−3,6−ジヒドロ−2H−ピリジン−1−カルバミン酸t−ブチル
MS(EI) m/z 239.4[M+H]+
MS(EI) m/z 213.4[M+H]+
MS(EI) m/z 361[M+H]+
MS(EI) m/z 261[M+H]+
MS(EI) m/z 462[M+H]+
60.a) (2RS)−アジドメチル−4−ベンジルモルホリン
MS(EI) m/z 236.2[M+H]+
THF/水(10/1、100ml)中の2−アジドメチル−4−ベンジルモルホリン(4.23g、18mmol)及びトリフェニルホスフィン(9.47g、36mmol)の溶液を60℃で一晩加熱した。反応混合物を濃縮して、残渣を3N HCl(200ml)及びEtOAc(200ml)中に溶解した。水相をEtOAc(4×)で抽出した。NaOHを用いて水相をpH12に調整し、EtOAc(2×200ml)で抽出して、MgSO4で乾燥し、濃縮した。
MS(EI) m/z 207.2[M+H]+
MS(EI) m/z 307.3[M+H]+
MS(EI) m/z 418.5[M+H]+
MS(EI) m/z 318.5[M+H]+
MS(EI) m/z 452.5[M+H]+
これらの化合物のMHK(μg/ml)を、以下の細菌株に関して測定した:黄色ブドウ球菌(S. aureus)ATCC 29213、黄色ブドウ球菌(S. aureus)I6、E.フェカリス(E. faecalis)ATCC 29212、E.フェシウム(E. faecium) vanA E25−1、インフルエンザ菌(H. influenzae)11、大腸菌(E. coli)ATCC 25922、M.カタラーリス(M. catarrhalis)117、肺炎連鎖球菌(S. pneumoniae)ATCC 49619。
Claims (13)
- 式(I)の化合物、あるいはそれらの薬理学的に許容可能な塩、溶媒和物、水和物又は薬理学的に許容可能な配合物:
(式中、
Aは、酸素、硫黄もしくは窒素原子、又はC1〜4アルキレン、C2〜4アルケニレン、C2〜4アルキニレンもしくはC1〜4ヘテロアルキレン基であり、
X1、X2、X3、X4及びX5は、それぞれ他のものと独立して、窒素原子又は式CR2の基であり、
R1は、水素原子、ハロゲン原子、ヒドロキシ基、アルキルオキシ基又はヘテロアルキルオキシ基であり、
R2は、水素原子、ハロゲン原子、又はヒドロキシ、アルキル、アルケニル、アルキニルもしくはヘテロアルキル基であり、
R3は、次の基から選択され:
R4基は、他のもの(複数可)とそれぞれ独立して、ヒドロキシ基、C1〜6アルキル基又はC1〜8ヘテロアルキル基であり、
R5は、アルキル、アルケニル、アルキニル、ヘテロアルキル、アリール、ヘテロアリール、シクロアルキル、アルキルシクロアルキル、ヘテロアルキルシクロアルキル、ヘテロシクロアルキル、アラルキル又はヘテロアラルキル基であり、
nは、0、1、2又は3であり、
mは、0又は2である)。 - Aは、酸素原子又は式CH2もしくはCH(OH)の基である、請求項1に記載の化合物。
- X1、X2、X3、X4及びX5の基の1つは窒素原子であり、かつ他のものはCH基であるか、又はX1、X2、X3、X4及びX5の基は全てCH基である、請求項1又は2に記載の化合物。
- R1は、ハロゲン原子、C1〜6アルキルオキシ基、メチル基又はエチル基である、請求項1ないし3のいずれか1項に記載の化合物。
- R1は、メトキシ基である、請求項1ないし4のいずれか1項に記載の化合物。
- R4は、個々のヘテロ原子として1個又は2個の酸素原子を有するC1〜6ヘテロアルキル基である、請求項1ないし5のいずれか1項に記載の化合物。
- R4は、式−COOH、−CH2COOH、−CH2CH2COOH、−CH2COOCH3、−CH2CH3、−CH2OH、−CH2CH2OH、−OH、−OCH3、−CH2OCONH2、−CH2CH2COOCH3、−COOCH3、−CH3又は(CH2)3OHの基である、請求項1ないし6のいずれか1項に記載の化合物。
- nは、0又は1である、請求項1ないし7のいずれか1項に記載の化合物。
- R5は、アラルキル基又はヘテロアラルキル基である、請求項1ないし8のいずれか1項に記載の化合物。
- R5は、式−Y−Cyの基であり、
Yは、C1〜C6アルキレン、C2〜C6アルケニレン又はC1〜C6ヘテロアルキレン基であり、ここで、任意に水素原子がヒドロキシ基で置換されていてもよく、あるいは2個の水素原子が=O基で置換されていてもよい、及び、
Cyは、任意に置換されたフェニル、ナフチル又は1個もしくは2個の環及び5〜10個の環原子を含有するヘテロアリール基、あるいは2個の環及び9個もしくは10個の環原子を含有する任意に置換されたアリールへテロシクロアルキル又はヘテロアリールへテロシクロアルキル基である、請求項1ないし9のいずれか1項に記載の化合物。 - R3は、次の基から選択される、請求項1ないし10のいずれか1項に記載の化合物:
。 - 請求項1ないし11のいずれか1項に記載の化合物、及び任意にキャリア物質及び/又はアジュバントを含む薬学的組成物。
- 細菌感染の治療における、請求項1ないし12のいずれか1項に記載の化合物又は薬学的組成物の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE2002147233 DE10247233A1 (de) | 2002-10-10 | 2002-10-10 | Neue Verbindungen, die Topoisomerase IV inhibieren |
DE10256405A DE10256405A1 (de) | 2002-12-02 | 2002-12-02 | Neue Verbindungen, die Topoisomerase IV inhibieren |
PCT/EP2003/011203 WO2004035569A2 (de) | 2002-10-10 | 2003-10-09 | Neue verbindungen mit antibakterieller aktivität |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2006505622A true JP2006505622A (ja) | 2006-02-16 |
JP2006505622A5 JP2006505622A5 (ja) | 2010-09-16 |
JP4602903B2 JP4602903B2 (ja) | 2010-12-22 |
Family
ID=32108775
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005501280A Expired - Fee Related JP4602903B2 (ja) | 2002-10-10 | 2003-10-09 | 抗菌活性を有する新規化合物 |
Country Status (12)
Country | Link |
---|---|
US (1) | US7223776B2 (ja) |
EP (2) | EP2239260A1 (ja) |
JP (1) | JP4602903B2 (ja) |
KR (1) | KR20050072432A (ja) |
CN (1) | CN101817815A (ja) |
AT (1) | ATE463494T1 (ja) |
AU (1) | AU2003301414B8 (ja) |
BR (1) | BR0315221A (ja) |
CA (1) | CA2500320A1 (ja) |
DE (1) | DE50312598D1 (ja) |
PL (1) | PL375525A1 (ja) |
WO (1) | WO2004035569A2 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009529525A (ja) * | 2006-03-10 | 2009-08-20 | アクテリオン ファーマシューティカルズ リミテッド | 抗菌性の化合物 |
JP2010527346A (ja) * | 2007-05-17 | 2010-08-12 | ヘルパービー セラピューティクス リミテッド | 臨床的に潜伏性の微生物を殺傷するための4−(ピロリジン−1−イル)キノリン化合物の使用 |
JP2010529983A (ja) * | 2007-06-15 | 2010-09-02 | アクテリオン ファーマシューティカルズ リミテッド | 3−アミノ−6−(1−アミノ−エチル)−テトラヒドロピラン誘導体 |
JP2012515745A (ja) * | 2009-01-21 | 2012-07-12 | バジリア ファルマスーチカ アーゲー | 新規二環式抗生物質 |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0112834D0 (en) | 2001-05-25 | 2001-07-18 | Smithkline Beecham Plc | Medicaments |
WO2003064431A2 (en) | 2002-01-29 | 2003-08-07 | Glaxo Group Limited | Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them |
EP2181996A1 (en) * | 2002-01-29 | 2010-05-05 | Glaxo Group Limited | Aminopiperidine derivatives |
AR040335A1 (es) * | 2002-06-26 | 2005-03-30 | Glaxo Group Ltd | Compuesto de ciclohexano o ciclohexeno, uso del mismo para preparar un medicamento, composicion farmaceutica que lo comprende, procedimiento y compuestos intermediarios de utilidad para preparar dicho compuesto |
AR040336A1 (es) * | 2002-06-26 | 2005-03-30 | Glaxo Group Ltd | Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para preparar dicho compuesto |
JP4704755B2 (ja) | 2002-11-05 | 2011-06-22 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 抗菌剤 |
DE60334016D1 (de) | 2002-11-05 | 2010-10-14 | Glaxo Group Ltd | Antibakterielle mittel |
EP1567520B1 (en) | 2002-12-04 | 2008-10-15 | Glaxo Group Limited | Quinolines and nitrogenated derivatives thereof and their use as antibacterial agents |
AR042486A1 (es) * | 2002-12-18 | 2005-06-22 | Glaxo Group Ltd | Compuesto de quinolina y naftiridina halosustituido en la posicion 3, procedimiento para preparar el compuesto, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion . |
EP1796466A4 (en) * | 2004-06-15 | 2009-09-02 | Glaxo Group Ltd | ANTIBACTERIAL AGENTS |
US20070254872A1 (en) * | 2004-07-08 | 2007-11-01 | Glaxo Group Limited | Antibacterial Agents |
WO2006020561A2 (en) * | 2004-08-09 | 2006-02-23 | Glaxo Group Limited | Antibacterial agents |
DE102004041163A1 (de) * | 2004-08-25 | 2006-03-02 | Morphochem Aktiengesellschaft für kombinatorische Chemie | Neue Verbindungen mit antibakterieller Aktivität |
JP4887297B2 (ja) * | 2004-09-24 | 2012-02-29 | アクテリオン ファーマシューティカルズ リミテッド | 新規二環式抗生物質 |
CN101039935B (zh) * | 2004-10-05 | 2011-04-20 | 埃科特莱茵药品有限公司 | 哌啶抗生素 |
MX2007012234A (es) | 2005-03-31 | 2008-03-18 | Johnson & Johnson | Compuestos de pirazol biciclico como agentes antibacterianos. |
MY150958A (en) * | 2005-06-16 | 2014-03-31 | Astrazeneca Ab | Compounds for the treatment of multi-drug resistant bacterial infections |
JO2952B1 (en) * | 2005-08-03 | 2016-03-15 | جانسين فارماسوتيكا ان. في | Quinoline derivatives acting as antibacterial agents |
CA2635126A1 (en) * | 2006-01-26 | 2007-08-02 | Actelion Pharmaceuticals Ltd | Tetrahydropyrane antibiotics |
JP5191053B2 (ja) * | 2006-02-15 | 2013-04-24 | アクテリオン ファーマシューティカルズ リミテッド | エタノールまたは1,2−エタンジオールシクロヘキシル抗生物質誘導体 |
WO2007115947A1 (en) | 2006-04-06 | 2007-10-18 | Glaxo Group Limited | Pyrrolo-quinoxalinone derivatives as antibacterials |
EP1992628A1 (en) | 2007-05-18 | 2008-11-19 | Glaxo Group Limited | Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones |
TW200819457A (en) | 2006-08-30 | 2008-05-01 | Actelion Pharmaceuticals Ltd | Spiro antibiotic derivatives |
US20100144717A1 (en) * | 2006-12-15 | 2010-06-10 | Janelle Comita-Prevoir | 2-quinolinone and 2-quinoxalinone-derivatives and their use as antibacterial agents |
CL2007003693A1 (es) | 2006-12-22 | 2008-06-27 | Actelion Pharmaceuticals Ltd | Compuestos derivados de pirido [3,2-b] [1,4] tiazina; composicion farmaceutica que contiene dichos compuestos; y su uso en el tratamiento de infecciones bacterianas. |
US9167869B2 (en) * | 2007-04-07 | 2015-10-27 | Dynasty Footwear, Ltd. | Shoe with multi-component embedded strap |
CL2008001003A1 (es) * | 2007-04-11 | 2008-10-17 | Actelion Pharmaceuticals Ltd | Compuestos derivados de oxazolidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion bacteriana. |
AU2008240764C1 (en) * | 2007-04-20 | 2011-10-20 | Glaxo Group Limited | Tricyclic nitrogen containing compounds as antibacterial agents |
EP2080761A1 (en) | 2008-01-18 | 2009-07-22 | Glaxo Group Limited | Compounds |
TW200944529A (en) | 2008-04-15 | 2009-11-01 | Actelion Pharmaceuticals Ltd | Tricyclic antibiotics |
WO2010043714A1 (en) | 2008-10-17 | 2010-04-22 | Glaxo Group Limited | Tricyclic nitrogen compounds used as antibacterials |
WO2010045987A1 (en) * | 2008-10-23 | 2010-04-29 | Glaxo Group Limited | Substituted (aza) -1-methyl-1h-quin0lin-2-0nes as antibacterials |
EP2379554B1 (en) | 2009-01-15 | 2015-11-11 | Glaxo Group Limited | Naphthyridin-2(1h)-one compounds useful as antibacterials |
PT3192500T (pt) | 2009-05-19 | 2021-01-05 | Neuroderm Ltd | Composições para a administração contínua de inibidores da dopa decarboxilase |
SG10201509316SA (en) * | 2010-11-15 | 2015-12-30 | Neuroderm Ltd | Continuous Administration Of L-Dopa, Dopa Decarboxylase Inhibitors, Catechol-O-Methyl Transferase Inhibitors And Compositions For Same |
DK2854764T3 (en) | 2012-06-05 | 2019-04-08 | Neuroderm Ltd | COMPOSITIONS CONTAINING APOMORPHINE AND ORGANIC ACIDS, AND APPLICATIONS THEREOF |
CA2887375C (en) * | 2012-10-10 | 2022-07-05 | Vitas Pharma Research Pvt Ltd | Inhibitors of dna gyrase for the treatment of bacterial infections |
US10258585B2 (en) | 2014-03-13 | 2019-04-16 | Neuroderm, Ltd. | DOPA decarboxylase inhibitor compositions |
ES2967693T3 (es) | 2014-03-13 | 2024-05-03 | Neuroderm Ltd | Composiciones del inhibidor de la dopa descarboxilasa |
EA031589B1 (ru) | 2014-08-22 | 2019-01-31 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Трициклические азотсодержащие соединения для лечения инфекции, вызываемой neisseria gonorrhoeae |
UY36851A (es) | 2015-08-16 | 2017-03-31 | Glaxosmithkline Ip Dev Ltd | Compuestos para uso en aplicaciones antibacterianas |
US11331293B1 (en) | 2020-11-17 | 2022-05-17 | Neuroderm, Ltd. | Method for treatment of Parkinson's disease |
US11844754B2 (en) | 2020-11-17 | 2023-12-19 | Neuroderm, Ltd. | Methods for treatment of Parkinson's disease |
US11213502B1 (en) | 2020-11-17 | 2022-01-04 | Neuroderm, Ltd. | Method for treatment of parkinson's disease |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US381462A (en) * | 1888-04-17 | Signments | ||
WO1996039145A1 (en) * | 1995-06-06 | 1996-12-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of her-2 autophosphorylation properties |
WO1999037635A1 (en) * | 1998-01-26 | 1999-07-29 | Smithkline Beecham Plc | Quinoline derivatives as antibacterials |
WO2000078748A1 (en) * | 1999-06-21 | 2000-12-28 | Smithkline Beecham P.L.C. | Quinoline derivatives as antibacterials |
WO2001007432A2 (en) * | 1999-07-23 | 2001-02-01 | Smithkline Beecham P.L.C. | Aminopiperidine derivatives as antibacterials |
WO2001046150A2 (en) * | 1999-12-20 | 2001-06-28 | Glaxo Group Limited | Quinolone compounds for use in treating viral infections |
WO2002008224A1 (en) * | 2000-07-26 | 2002-01-31 | Smithkline Beecham P.L.C. | Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity |
WO2002024684A1 (en) * | 2000-09-21 | 2002-03-28 | Smithkline Beecham P.L.C. | Quinoline derivatives as antibacterials |
WO2002056882A1 (en) * | 2001-01-22 | 2002-07-25 | Smithkline Beecham P.L.C. | Quinolines and nitrogenated derivaive thereof substituted in 4-position by a piperidine-containing moiety and their use as antibacterial agents |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL265777A (ja) * | 1960-06-09 | |||
FR2798656B1 (fr) * | 1999-09-17 | 2004-12-17 | Aventis Pharma Sa | Derives de la quinolyl propyl piperidine, leur preparation et les compositions qui les contiennent |
CA2426706A1 (en) | 2000-10-26 | 2002-05-02 | Smithkline Beecham P.L.C. | Benzoxazinone derivatives, their preparation and use |
GB0031088D0 (en) * | 2000-12-20 | 2001-01-31 | Smithkline Beecham Plc | Medicaments |
GB0031086D0 (en) | 2000-12-20 | 2001-01-31 | Smithkline Beecham Plc | Medicaments |
GB0118238D0 (en) | 2001-07-26 | 2001-09-19 | Smithkline Beecham Plc | Medicaments |
-
2003
- 2003-10-09 CA CA002500320A patent/CA2500320A1/en not_active Abandoned
- 2003-10-09 JP JP2005501280A patent/JP4602903B2/ja not_active Expired - Fee Related
- 2003-10-09 PL PL03375525A patent/PL375525A1/xx not_active Application Discontinuation
- 2003-10-09 CN CN200910209212A patent/CN101817815A/zh active Pending
- 2003-10-09 BR BR0315221-9A patent/BR0315221A/pt not_active IP Right Cessation
- 2003-10-09 KR KR1020057006098A patent/KR20050072432A/ko not_active Application Discontinuation
- 2003-10-09 EP EP10003710A patent/EP2239260A1/de not_active Withdrawn
- 2003-10-09 AT AT03808720T patent/ATE463494T1/de not_active IP Right Cessation
- 2003-10-09 DE DE50312598T patent/DE50312598D1/de not_active Expired - Lifetime
- 2003-10-09 AU AU2003301414A patent/AU2003301414B8/en not_active Ceased
- 2003-10-09 EP EP03808720A patent/EP1551829B1/de not_active Expired - Lifetime
- 2003-10-09 WO PCT/EP2003/011203 patent/WO2004035569A2/de active Application Filing
- 2003-10-09 US US10/529,986 patent/US7223776B2/en not_active Expired - Fee Related
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US381462A (en) * | 1888-04-17 | Signments | ||
WO1996039145A1 (en) * | 1995-06-06 | 1996-12-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of her-2 autophosphorylation properties |
WO1999037635A1 (en) * | 1998-01-26 | 1999-07-29 | Smithkline Beecham Plc | Quinoline derivatives as antibacterials |
WO2000078748A1 (en) * | 1999-06-21 | 2000-12-28 | Smithkline Beecham P.L.C. | Quinoline derivatives as antibacterials |
WO2001007432A2 (en) * | 1999-07-23 | 2001-02-01 | Smithkline Beecham P.L.C. | Aminopiperidine derivatives as antibacterials |
WO2001046150A2 (en) * | 1999-12-20 | 2001-06-28 | Glaxo Group Limited | Quinolone compounds for use in treating viral infections |
WO2002008224A1 (en) * | 2000-07-26 | 2002-01-31 | Smithkline Beecham P.L.C. | Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity |
WO2002024684A1 (en) * | 2000-09-21 | 2002-03-28 | Smithkline Beecham P.L.C. | Quinoline derivatives as antibacterials |
WO2002056882A1 (en) * | 2001-01-22 | 2002-07-25 | Smithkline Beecham P.L.C. | Quinolines and nitrogenated derivaive thereof substituted in 4-position by a piperidine-containing moiety and their use as antibacterial agents |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009529525A (ja) * | 2006-03-10 | 2009-08-20 | アクテリオン ファーマシューティカルズ リミテッド | 抗菌性の化合物 |
JP2010527346A (ja) * | 2007-05-17 | 2010-08-12 | ヘルパービー セラピューティクス リミテッド | 臨床的に潜伏性の微生物を殺傷するための4−(ピロリジン−1−イル)キノリン化合物の使用 |
JP2010529983A (ja) * | 2007-06-15 | 2010-09-02 | アクテリオン ファーマシューティカルズ リミテッド | 3−アミノ−6−(1−アミノ−エチル)−テトラヒドロピラン誘導体 |
JP2012515745A (ja) * | 2009-01-21 | 2012-07-12 | バジリア ファルマスーチカ アーゲー | 新規二環式抗生物質 |
Also Published As
Publication number | Publication date |
---|---|
KR20050072432A (ko) | 2005-07-11 |
CA2500320A1 (en) | 2004-04-29 |
WO2004035569A3 (de) | 2004-09-02 |
US7223776B2 (en) | 2007-05-29 |
AU2003301414B2 (en) | 2010-05-13 |
EP1551829A2 (de) | 2005-07-13 |
DE50312598D1 (de) | 2010-05-20 |
BR0315221A (pt) | 2005-08-23 |
EP1551829B1 (de) | 2010-04-07 |
JP4602903B2 (ja) | 2010-12-22 |
PL375525A1 (en) | 2005-11-28 |
EP2239260A1 (de) | 2010-10-13 |
CN101817815A (zh) | 2010-09-01 |
US20060040949A1 (en) | 2006-02-23 |
AU2003301414A1 (en) | 2004-05-04 |
AU2003301414B8 (en) | 2010-06-17 |
ATE463494T1 (de) | 2010-04-15 |
WO2004035569A2 (de) | 2004-04-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4602903B2 (ja) | 抗菌活性を有する新規化合物 | |
RU2397982C2 (ru) | Новые соединения с антибактериальным действием | |
KR20070045152A (ko) | 항세균 활성을 갖는 신규 화합물 | |
US20080280879A1 (en) | Substituted heterocyclic derivatives and their pharmaceutical use and compositions | |
JP2009511530A (ja) | 抗菌活性を有する5−キノリン誘導体 | |
KR20150124985A (ko) | 베타-세크레타제 억제제로서 퍼플루오르화된 사이클로프로필 융합된 1,3-옥사진-2-아민 화합물 및 그의 사용 방법 | |
CA2570183A1 (en) | Substituted n-arylsulfonylheterocyclic amines as gamma-secretase inhibitors | |
WO2007062007A1 (en) | Beta-secretase modulators and methods of use | |
AU2010212235A1 (en) | Derivatives of azaspiranyl-alkylcarbamates of 5-member heterocyclic compounds, preparation thereof and therapeutic use thereof | |
NO173652B (no) | Analogifremgangsmaate ved fremstilling av et terapeutisk aktivt indazol-3-karboksylsyrederivat | |
JP2007508260A (ja) | 新規なテトラヒドロピリジン誘導体 | |
AU2010332767B2 (en) | Tricyclic antibiotics | |
NZ539217A (en) | Bicyclic quinoline derivative compounds having antibacterial activity | |
JP2014517019A (ja) | 三環式抗生物質 | |
JP2000038386A (ja) | 新規ナフチリジン誘導体またはその塩 | |
MX2008004780A (es) | Derivado activo 5-quinolina antibacteriano |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060904 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060904 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100122 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100308 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100315 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100721 |
|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20100721 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100907 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100930 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131008 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060904 |
|
LAPS | Cancellation because of no payment of annual fees |